

RESEARCH MONOGRAPH . COMPOUND PROFILE

Palmitoylethanolamide

An endogenous fatty acid amide biosynthesized from membrane phospholipids, identified as an anti-inflammatory factor in the 1950s and subsequently characterized as a peroxisome proliferator-activated receptor alpha agonist with broad analgesic, anti-inflammatory, neuroprotective, and mast cell stabilizing activity across chronic pain, neuroinflammation, and neurodegenerative disease models.

DOCUMENT	KDC-MN-1494
ISSUED	2026-05-13
REVISION	1.0
AUTHOR	Kodi <i>ac</i> biolabs Research
COMPOUND CLASS	Endogenous N-acylethanolamide lipid mediator with peroxisome proliferator-activated receptor alpha agonism and mast cell modulatory activity

ABSTRACT

Palmitoylethanolamide (PEA; CAS 544-31-0; molecular formula $C_{18}H_{37}NO_2$; molecular weight 299.49 g/mol) is an endogenous fatty acid amide of the N-acylethanolamide class, biosynthesized on demand from membrane N-palmitoyl-phosphatidylethanolamine by the enzyme N-acyl-phosphatidylethanolamine-selective phospholipase D (NAPE-PLD) and degraded principally by fatty acid amide hydrolase (FAAH) and N-acylethanolamine-hydrolyzing acid amidase (NAAA) to palmitic acid and ethanolamine. The compound was first identified as a crystalline anti-inflammatory factor isolated from soybean lecithin by Kuehl et al. in 1957, following earlier observations by Coburn et al. (1954) that egg yolk protected against experimental anaphylactic arthritis. The Nobel laureate Rita Levi-Montalcini and colleagues subsequently characterized PEA as a modulator of mast cell degranulation and proposed the autacoid local injury antagonism (ALIA) mechanism in 1993, establishing the conceptual framework for PEA as an endogenous resolution factor in inflammation.

The principal molecular target of PEA is the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha), at which PEA acts as a direct agonist with an EC₅₀ of approximately 3.1 micromolar in cell-based reporter assays. Lo Verme et al. (2005) demonstrated that the anti-inflammatory actions of PEA in carrageenan-induced paw edema and phorbol ester-induced ear edema models are abolished in PPAR-alpha knockout mice, establishing PPAR-alpha as the principal mediator of PEA anti-inflammatory pharmacology. Additional receptor targets include the orphan G-protein coupled receptors GPR55 and GPR119, the transient receptor potential vanilloid type 1 channel (TRPV1, via indirect potentiation), and a mast cell surface receptor pharmacologically consistent with a peripheral cannabinoid site. PEA does not bind with meaningful affinity to classical cannabinoid receptors CB1 or CB2 but modulates the endocannabinoid system indirectly through an entourage mechanism: competition for FAAH-mediated degradation elevates tissue levels of the

endocannabinoid anandamide, thereby potentiating anandamide signaling at CB1, CB2, and TRPV1.

The clinical evidence base for PEA spans chronic pain, neuropathic pain, neuroinflammation, and neurodegenerative disease. A 2023 systematic review and meta-analysis of double-blind randomized controlled trials (Scuteri et al., *Nutrients*, 2023) encompassing 12 studies and approximately 1300 patients demonstrated that oral PEA at 300 to 1200 mg daily produces statistically significant and clinically meaningful pain intensity reduction compared to placebo or active control, with effect emerging at 30 days and increasing through 60 days of treatment. Specific indications with positive randomized controlled trial evidence include sciatic pain, diabetic peripheral neuropathy, carpal tunnel syndrome, temporomandibular joint disorder, chronic low back pain, endometriosis-associated pelvic pain, and fibromyalgia. Micronized (mPEA) and ultramicronized (umPEA) particle-size formulations have been developed to overcome the poor aqueous solubility and limited oral bioavailability of native crystalline PEA, with the micronization process increasing the specific surface area and producing substantially improved absorption and tissue distribution.

PEA exhibits a favorable safety profile consistent with its status as an endogenous compound and a natural component of the human diet (present in egg yolk, soybean lecithin, peanut meal, and other food sources). Across more than 40 clinical studies and approximately 3000 patient-exposures, no serious adverse drug reactions have been attributed to PEA supplementation at doses up to 1200 mg daily for up to 120 days. The compound is marketed as a medical food or dietary supplement in multiple European jurisdictions (Normast, PeaPure, Levagen) and is available as a research-grade preparation from multiple chemical suppliers. PEA is not approved as a drug by the United States Food and Drug Administration or by the European Medicines Agency; its regulatory status varies by jurisdiction between dietary supplement, medical food, and food for special medical purposes.

This monograph documents the chemistry, biosynthesis, and degradation of PEA; the multi-target molecular pharmacology

including PPAR-alpha agonism, GPR55 and GPR119 signaling, mast cell modulation, and entourage potentiation of endocannabinoid tone; the pharmacokinetic profile with emphasis on formulation-dependent bioavailability; the preclinical pharmacology across pain, inflammation, and neurodegeneration models; the clinical evidence base in chronic and neuropathic pain, neuroinflammatory conditions, and neurodegenerative disease; sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signal; and a comparative assessment of five alternative anti-inflammatory lipid mediators (cannabidiol, oleoylethanolamide, stearoylethanolamide, N-arachidonylethanolamide, and resolvin E1) against PEA on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Palmitoylethanolamide. The compound does not hold a formal INN assigned by the World Health Organization; palmitoylethanolamide is the conventional chemical name used in pharmacological and clinical literature.

Common abbreviation: PEA.

Marketed and commercial names: Normast (Epitech Group, Italy), PeaPure (JP Russell Science, Netherlands), Levagen (Gencor Pacific), Palmidrol (historical designation in some European pharmacopoeias), Impulsin (historical designation in early clinical studies of anti-influenza activity in Czechoslovakia in the 1970s).

Chemical Abstracts Service registry number: 544-31-0.

PubChem CID: 4671.

International Union of Pure and Applied Chemistry name: N-(2-hydroxyethyl)hexadecanamide. The compound is the amide of palmitic acid (hexadecanoic acid, C16:0) and ethanolamine (2-aminoethanol).

Other chemical names: N-palmitoylethanolamine, N-(2-hydroxyethyl)palmitamide, palmidrol.

1.2 Structural class and chemistry

Palmitoylethanolamide is a member of the N-acylethanolamide (NAE) family, a class of endogenous lipid signaling molecules that includes anandamide (N-arachidonoylethanolamide, AEA), oleoylethanolamide (OEA), and stearoylethanolamide (SEA). The NAEs are fatty acid amides formed by conjugation of a fatty acid with ethanolamine through an amide bond. PEA is the saturated C16 member of the series [1, 2].

Molecular formula: C₁₈H₃₇NO₂.

Exact mass: 299.2824 g/mol (monoisotopic).

Molecular weight: 299.49 g/mol.

Physical properties: White to off-white waxy solid or crystalline powder. Melting point approximately 93 to 98 degrees Celsius. Highly lipophilic; practically insoluble in water (aqueous solubility less than 1 microgram per milliliter at 25 degrees Celsius). Freely soluble in dimethyl sulfoxide, ethanol, chloroform, and methanol. The poor aqueous solubility is the principal pharmaceutical challenge and the basis for the development of micronized and ultramicronized formulations [3].

Stereochemistry: PEA contains no stereocenters. The molecule is achiral.

Endogenous distribution: PEA is present in mammalian tissues including brain, spinal cord, skin, liver, intestinal mucosa, skeletal muscle, and immune cells (mast cells, macrophages, monocytes). Tissue concentrations in the nanomolar to low-micromolar range have been measured in healthy brain and are elevated in damaged or inflamed tissue, consistent with an on-demand biosynthetic response to cellular stress [4, 5]. PEA is also a natural component of the human diet, present in egg yolk, soybean lecithin, peanut meal, corn, tomato, and several other plant and animal food sources [1].

1.3 Biosynthesis and degradation

PEA is biosynthesized in mammalian cells from membrane phospholipid precursors through a two-step pathway. The first step is the transfer of a palmitoyl group from the sn-1 position of phosphatidylcholine to the primary amine of phosphatidylethanolamine, catalyzed by a calcium-dependent N-acyltransferase, producing N-palmitoyl-phosphatidylethanolamine (NPPE). The second step is the hydrolysis of NPPE by the enzyme N-acyl-phosphatidylethanolamine-selective phospholipase D (NAPE-PLD), releasing PEA and phosphatidic acid [2, 6].

Degradation of PEA proceeds through hydrolysis of the amide bond to yield palmitic acid and ethanolamine. Two enzymes catalyze this reaction: fatty acid amide hydrolase (FAAH), a serine hydrolase expressed at high levels in brain, liver, and kidney; and N-acylethanolamine-hydrolyzing acid amidase (NAAA), a cysteine hydrolase expressed at high levels in macrophages, intestinal mucosa, and lung tissue. NAAA is the more selective enzyme for PEA degradation under physiological conditions, operating at acidic pH consistent with lysosomal localization. FAAH, which has a broader substrate profile and neutral pH optimum, degrades PEA, anandamide, oleoylethanolamide, and other fatty acid amides with comparable efficiency [7, 8].

The biosynthetic pathway is activated by cellular stress signals including calcium influx, inflammatory mediators, and tissue injury, producing a local elevation of PEA concentration at sites of damage or inflammation. This on-demand biosynthesis, coupled with local degradation, establishes PEA as a prototypical autacoid: a local mediator synthesized and acting near its site of production [4].

2. Abstract

Palmitoylethanolamide (PEA) is an endogenous N-acylethanolamide lipid mediator that acts as a direct agonist at the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha), a modulator of mast cell degranulation, an agonist at the orphan receptors GPR55 and GPR119, and an indirect potentiator of endocannabinoid signaling through competition for the degradative enzyme fatty acid amide hydrolase (FAAH). The compound was identified as a crystalline anti-inflammatory factor from soybean lecithin in 1957 by Kuehl et al. [1] and was subsequently characterized by Levi-Montalcini and colleagues as a mast cell modulatory autacoid [9]. The identification of PPAR-alpha as the principal molecular target by Lo Verme et al. in 2005 [10] provided the mechanistic basis for the anti-inflammatory, analgesic, and neuroprotective effects observed across a broad preclinical and clinical pharmacology.

PEA does not bind classical cannabinoid receptors CB1 or CB2 with meaningful affinity. Its relationship to the endocannabinoid system is indirect, operating through the entourage mechanism first proposed by Ben-Shabat et al. (1998) [11]: by competing with anandamide for FAAH-mediated degradation, PEA elevates local anandamide concentrations and thereby potentiates anandamide signaling at cannabinoid and vanilloid receptors. This entourage activity, combined with direct PPAR-alpha agonism and mast cell stabilization, produces a composite pharmacological profile that is anti-inflammatory, analgesic, and neuroprotective without the psychoactive, sedative, or reinforcing properties associated with direct cannabinoid receptor activation.

The clinical evidence base encompasses chronic and neuropathic pain, where multiple randomized controlled trials and meta-analyses have demonstrated statistically significant pain reduction with oral PEA at 300 to 1200 mg daily [12, 13, 14]. Specific pain indications with positive trial evidence include sciatic pain, diabetic peripheral neuropathy, carpal tunnel syndrome, temporomandibular joint disorder, chronic low back pain, and endometriosis-associated pelvic pain. Emerging evidence supports efficacy in neuroinflammatory and neurodegenerative conditions, including multiple sclerosis, Alzheimer disease, and stroke recovery, though the neurodegenerative evidence remains principally preclinical with limited clinical translation [15, 16].

A central pharmaceutical challenge is the poor aqueous solubility of native crystalline PEA, which limits oral bioavailability. Micronized (mPEA) and ultramicrosized (umPEA) formulations reduce particle size to the 2 to 10 micrometer and 0.8 to 6 micrometer range, respectively, increasing the specific surface area and producing substantially improved dissolution, absorption, and tissue distribution [3, 17]. The micronized and ultramicrosized formulations are the basis of the clinical efficacy evidence and are the preparations used in the majority of published randomized controlled trials.

PEA is well tolerated across all studied populations and dosing regimens. No serious adverse drug reactions have been attributed to PEA in the published clinical literature. The compound is marketed as a medical food, food for special medical purposes, or dietary supplement in multiple European jurisdictions and in Australia, and is available as a research-grade preparation from multiple chemical suppliers. It is not approved as a drug by any major regulatory authority.

3. Discovery and Development History

3.1 Origin and early identification

The anti-inflammatory activity later attributed to PEA was first observed by Coburn and colleagues in 1954, who reported that dried egg yolk, administered orally to guinea pigs, protected the animals from joint inflammation induced by experimental anaphylactic arthritis [18]. The active fraction was in the lipid-soluble component. Long and Martin (1956) purified an antiallergic factor from egg yolk that had biological and chemical similarity to preparations obtained earlier from peanut meal [19].

The identification of the specific chemical entity was accomplished by Kuehl et al. in 1957, who isolated a crystalline anti-inflammatory compound from soybean lecithin and identified it by infrared spectroscopy and elemental analysis as N-(2-hydroxyethyl)palmitamide [1]. Kuehl and colleagues demonstrated that the compound was present in several food sources and that it reduced local joint swelling in a guinea pig passive arthritis model. This 1957 report is the canonical discovery publication for PEA.

3.2 Czechoslovak clinical studies (1960s to 1970s)

In the 1960s and 1970s, PEA was investigated in Czechoslovakia under the name Impulsin as a prophylactic agent against respiratory viral infections, including influenza and the common cold. A series of clinical studies in military recruits and industrial workers demonstrated modest protective effects against upper respiratory infection incidence and severity [20]. These studies, conducted before the era of modern randomized controlled trial methodology, are historically significant as the first human clinical applications of PEA but are methodologically limited by contemporary standards.

3.3 Levi-Montalcini and the ALIA mechanism

Rita Levi-Montalcini, the Nobel laureate recognized for the discovery of nerve growth factor, and her research group at the Institute of Neurobiology in Rome, characterized PEA in the early 1990s as a modulator of mast cell activation. Aloe et al. (1993) demonstrated that PEA downregulated mast cell degranulation and reduced the release of histamine, tumor necrosis factor alpha, and other pre-formed and newly synthesized mediators [9]. Levi-Montalcini proposed the autacoid local injury antagonism (ALIA) mechanism, a conceptual framework positing that PEA and related endogenous lipid amides serve as local protective factors that counteract excessive inflammatory and immune activation at sites of tissue injury. The ALIA concept anticipated by a decade the later identification of PPAR-alpha as the molecular target and established the intellectual foundation for PEA as an endogenous resolution mediator [21].

3.4 Identification of PPAR-alpha as the molecular target

The mechanistic basis for PEA anti-inflammatory pharmacology was established by Lo Verme et al. (2005) in the laboratory of Daniele Piomelli at the University of California, Irvine [10]. Using PPAR-alpha knockout mice, Lo Verme demonstrated that the anti-inflammatory effects of PEA in car-

rageenan-induced paw edema and phorbol ester-induced ear edema were abolished in the absence of the receptor, while wild-type mice showed dose-dependent inhibition. The EC₅₀ for PEA activation of PPAR- α in cell-based reporter assays was approximately 3.1 micromolar. This report transformed PEA pharmacology from a descriptive mast cell phenomenon to a receptor-mediated nuclear signaling mechanism with clear downstream transcriptional consequences.

3.5 Development of micronized formulations and clinical translation

The poor aqueous solubility of native PEA (less than 1 microgram per milliliter) limited its oral bioavailability and clinical utility. In the 2000s, the Italian pharmaceutical company Epitech Group developed micronized (mPEA) and ultramicronized (umPEA) formulations using jet-milling technology to reduce particle size and increase specific surface area [3, 17]. The micronized formulations demonstrated substantially improved oral absorption in preclinical pharmacokinetic studies and became the basis of the marketed product Normast, introduced in Italy as a food for special medical purposes for chronic and neuropathic pain.

The subsequent decade produced a substantial clinical trial literature, with more than 40 clinical studies evaluating micronized and ultramicronized PEA across pain, neuroinflammatory, and neurodegenerative indications. The compound is now marketed in multiple European countries, Australia, and other jurisdictions, and is the subject of ongoing clinical investigation in additional indications.

4. Mechanism of Action

PEA is a multi-target lipid mediator. Its principal molecular activities, characterized in knockout mouse models, heterologous expression systems, and native tissue preparations, are agonism at the nuclear receptor PPAR-alpha; modulation of mast cell activation; agonism at the orphan G-protein coupled receptors GPR55 and GPR119; indirect potentiation of endocannabinoid signaling through the entourage mechanism; and indirect activation of the TRPV1 channel. These activities operate at physiologically relevant concentrations and contribute differentially to the observed anti-inflammatory, analgesic, and neuroprotective effects.

4.1 PPAR-alpha agonism

The peroxisome proliferator-activated receptor alpha (PPAR-alpha) is a ligand-activated nuclear transcription factor of the PPAR subfamily, expressed at high levels in liver, kidney, heart, skeletal muscle, and at moderate levels in neurons, astrocytes, and microglia. Upon ligand binding, PPAR-alpha heterodimerizes with the retinoid X receptor (RXR) and binds to peroxisome proliferator response elements (PPREs) in the promoter regions of target genes, transactivating genes involved in fatty acid oxidation, ketogenesis, and anti-inflammatory signaling [10, 22].

PEA binds and activates PPAR-alpha with an EC₅₀ of approximately 3.1 micromolar in reporter gene assays. The anti-inflammatory consequences of PPAR-alpha activation by PEA include suppression of NF-kappaB-driven transcription of proinflammatory cytokines (tumor necrosis factor alpha, interleukin-1 beta, interleukin-6), reduction of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) expression, and inhibition of IkappaB-alpha degradation and p65 NF-kappaB nuclear translocation [10, 22]. These transcriptional consequences are abolished in PPAR-alpha knockout mice, confirming the receptor dependence of the anti-inflammatory mechanism.

In the central nervous system, PPAR-alpha activation by PEA modulates microglial and astrocytic inflammatory responses, reduces reactive gliosis, and preserves neuronal viability in models of excitotoxicity, ischemia, and neurodegeneration [15, 16]. The neuroprotective mechanism is therefore a downstream consequence of the same PPAR-alpha-mediated transcriptional program that mediates peripheral anti-inflammatory activity.

4.2 Mast cell modulation and the ALIA mechanism

PEA downregulates mast cell degranulation and reduces the release of preformed mediators (histamine, beta-hexosaminidase, tryptase) and newly synthesized mediators (tumor necrosis factor alpha, prostaglandin D₂, nerve growth factor) from activated mast cells [9, 23]. The mast cell modulatory effect was the first characterized mechanism of PEA action, described by the Levi-Montalcini group before the identification of PPAR-alpha as the molecular target.

The receptor mediating mast cell modulation is not fully resolved. Facci et al. (1995) reported that mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and PEA: PEA downmodulated mast cell activation through this receptor, while anandamide acted as a

competitive antagonist at the same site [24]. The receptor was pharmacologically consistent with CB2 but showed differential agonist sensitivity from classical CB2-mediated responses. More recent work suggests that the mast cell modulatory effect may involve PPAR-alpha, GPR55, or both, in addition to or instead of a classical cannabinoid receptor [22, 25].

The ALIA mechanism posits that PEA is biosynthesized at sites of tissue injury in proportion to the inflammatory stimulus and acts locally to dampen excessive mast cell activation, thereby limiting the amplification of the inflammatory cascade. Mast cells are sentinel immune cells positioned at tissue interfaces (skin, mucosa, nerve sheaths) and are critical amplifiers of neuroinflammation, pain sensitization, and allergic responses. PEA modulation of mast cell activation is therefore the mechanistic basis for the analgesic and anti-neuroinflammatory effects observed in peripheral neuropathy, sciatic pain, and dermatological conditions [21, 23].

4.3 GPR55 and GPR119 signaling

GPR55 is an orphan G-protein coupled receptor expressed in brain (particularly hippocampus and striatum), adrenal gland, gastrointestinal tract, and immune cells. PEA activates GPR55 and stimulates intracellular calcium mobilization and ERK1/2 phosphorylation [26, 27]. Lauckner et al. (2008) characterized PEA as a GPR55 agonist, and subsequent work by Deliu et al. (2015) demonstrated that PEA modulates mesolimbic dopamine activity and social interaction behavior in rodents through GPR55 signaling in the ventral hippocampus [28]. The GPR55 mechanism may contribute to the anxiolytic and procognitive effects reported in some preclinical models.

GPR119 is expressed primarily in pancreatic beta cells and enteroendocrine L-cells. PEA activation of GPR119 stimulates glucagon-like peptide 1 (GLP-1) secretion and promotes insulin release, providing a mechanistic link between PEA and glucose homeostasis [27]. The metabolic implications of GPR119 activation by PEA are a subject of active investigation but have not yet produced clinical evidence.

4.4 Entourage effect and indirect endocannabinoid potentiation

PEA does not bind CB1 or CB2 receptors with pharmacologically relevant affinity. However, PEA modulates the endocannabinoid system indirectly through the entourage mechanism. PEA and anandamide are both substrates for FAAH; PEA competition for FAAH active sites reduces anandamide degradation and elevates local anandamide concentrations [11, 29]. Elevated anandamide, in turn, activates CB1 receptors (producing analgesic and anxiolytic effects), CB2 receptors (producing anti-inflammatory effects), and TRPV1 channels (producing antinociceptive effects at desensitizing concentrations).

Additionally, PEA has been reported to allosterically potentiate anandamide activity at TRPV1 through a PPAR-alpha-dependent mechanism: PPAR-alpha activation by PEA upregulates TRPV1 expression and sensitizes the channel to anandamide activation, producing a dual potentiation of the vanilloid nociceptive pathway [30]. This PPAR-alpha-to-TRPV1 axis represents a convergence of the nuclear receptor and endocannabinoid mechanisms.

4.5 Composite pharmacology

The composite pharmacological profile of PEA is therefore a multi-level anti-inflammatory and analgesic mechanism operating through nuclear transcription (PPAR-alpha), membrane receptor signaling (GPR55, GPR119), cellular effector modulation (mast cell stabilization), and lipid mediator network regulation (entourage potentiation of anandamide). This mechanistic diversity distinguishes PEA from single-target anti-inflammatory agents and from direct cannabinoid receptor agonists, and provides a pharmacological basis for activity across a broad range of inflammatory, nociceptive, and neuroinflammatory conditions without the psychoactive, sedative, or abuse-liability profiles associated with cannabinoid receptor agonism.

5. Pharmacokinetics and Routes of Administration

5.1 Absorption

PEA is a highly lipophilic compound with poor aqueous solubility (less than 1 microgram per milliliter), presenting a significant pharmaceutical challenge for oral delivery. Native crystalline PEA has limited oral bioavailability; the large crystal size and hydrophobic character restrict dissolution in the aqueous environment of the gastrointestinal tract [3, 17].

Micronized PEA (mPEA; particle size 2 to 10 micrometers) and ultramicronized PEA (umPEA; particle size 0.8 to 6 micrometers) produced by jet-milling technology substantially improve oral absorption. The micronization process increases the specific surface area of the powder, enhancing the dissolution rate and promoting more complete intestinal absorption. Preclinical studies in rats demonstrated that ultramicronized PEA produced plasma concentrations approximately 1.5 to 2-fold higher than equimolar doses of native crystalline PEA, with faster time to peak concentration [3, 17].

Time to peak plasma concentration after oral administration of micronized PEA in humans is approximately 1 to 2 hours. Food effects on absorption have not been fully characterized in published pharmacokinetic studies, but coadministration with a lipid-containing meal is generally recommended on the basis of the lipophilic character of the compound.

5.2 Distribution

PEA is distributed widely in mammalian tissues, with the highest endogenous concentrations in brain, spinal cord, skin, liver, and immune-competent tissues. Exogenous PEA administered orally distributes to peripheral and central compartments. Brain penetration has been demonstrated in rodent studies: oral administration of micronized PEA increases brain PEA concentrations above endogenous baseline within 2 hours of dosing [15, 31].

Plasma protein binding has not been precisely characterized in published literature. The lipophilic character suggests moderate to high binding to albumin and lipoproteins. The volume of distribution has not been formally reported in human pharmacokinetic studies.

5.3 Metabolism

PEA is metabolized by hydrolysis of the amide bond to yield palmitic acid and ethanolamine. The two principal hydrolytic enzymes are FAAH (expressed at high levels in brain, liver, and kidney, with a neutral pH optimum) and NAAA (expressed at high levels in macrophages, lung, and intestinal mucosa, with an acidic pH optimum consistent with lysosomal localization) [7, 8]. NAAA is the more selective enzyme for PEA and is considered the principal catabolic enzyme under physiological conditions, while FAAH plays a greater role in the catabolism of exogenous PEA delivered at supraphysiological concentrations.

The metabolic products, palmitic acid and ethanolamine, are ordinary metabolites integrated into standard lipid and amino-alcohol metabolism. Palmitic acid enters beta-oxidation or is recycled into membrane phospholipids; ethanolamine is utilized in phosphatidylethanolamine biosynthesis. There are no known active or toxic metabolites of PEA [7].

5.4 Elimination

The plasma half-life of exogenous PEA in humans has not been precisely characterized in comprehensive pharmacokinetic studies. Based on the rapid enzymatic hydrolysis by FAAH and NAAA and the endogenous turnover kinetics, the functional half-life is estimated at approximately 1 to 4 hours for the micronized formulations. The rapid metabolism supports twice-daily dosing regimens, which are the standard in clinical trials.

Elimination is predominantly metabolic. Renal excretion of intact PEA is negligible owing to the lipophilic character and rapid hydrolysis. The metabolic products are excreted through standard fatty acid and amino-alcohol elimination pathways.

5.5 Routes of administration

Oral administration is the standard route in clinical use and research. Typical formulations include micronized or ultramicronized PEA in tablets, capsules, sachets, or sublingual preparations at 300 mg, 400 mg, or 600 mg per unit dose. The standard clinical dosing regimen is 600 mg twice daily (1200 mg total daily dose) for chronic pain and neuroinflammatory indications, with some studies using 300 mg twice daily (600 mg total daily dose) [12, 13, 14].

Topical formulations (creams, gels) containing PEA at 1 to 2 percent concentration have been used in dermatological research for eczema, pruritus, and localized pain. Topical PEA penetrates the stratum corneum and produces local anti-inflammatory and antipruritic effects consistent with mast cell modulation in the dermis [32].

Parenteral formulations have not been developed for clinical use. Research-grade PEA dissolved in dimethyl sulfoxide or ethanol vehicle has been administered intraperitoneally and intrathecally in rodent studies.

5.6 Formulation considerations

The choice of formulation is a critical determinant of clinical efficacy. The majority of positive randomized controlled trials have used micronized or ultramicronized PEA (Normast, Levagen, or equivalent preparations). Studies using native crystalline PEA at the same doses may produce smaller or absent effects owing to reduced bioavailability. Investigators should specify the formulation and particle size in study design and should not assume bioequivalence between native and micronized preparations [3, 17].

6. Preclinical Pharmacology

6.1 Anti-inflammatory models

PEA produces dose-dependent anti-inflammatory effects in multiple rodent models. In the carrageenan-induced paw edema model, PEA at 10 mg/kg intraperitoneally reduces edema volume by approximately 40 to 60 percent; this effect is abolished in PPAR-alpha knockout mice [10]. In the phorbol ester-induced ear edema model, PEA at 1 to 10 mg/kg reduces ear thickness and myeloperoxidase activity (a marker of neutrophil infiltration) in a dose-dependent manner [10, 22].

PEA modulates neuroinflammation in models of spinal cord injury, traumatic brain injury, and experimental autoimmune encephalomyelitis (a model of multiple sclerosis). In the spinal cord compression model, ultramicrosized PEA at 10 mg/kg daily reduces astrocyte and microglial activation, suppresses proinflammatory cytokine expression, and improves locomotor recovery scores [15, 33].

6.2 Nociceptive and neuropathic pain models

PEA produces antinociceptive effects in both inflammatory and neuropathic pain models. In the formalin test (a model of persistent inflammatory pain), PEA at 10 to 30 mg/kg reduces second-phase nociceptive behavior. In the chronic constriction injury model of neuropathic pain, chronic PEA administration (10 mg/kg daily for 7 to 14 days) reduces mechanical allodynia and thermal hyperalgesia [34, 35].

The antinociceptive mechanism involves both peripheral and central components: peripheral PPAR-alpha activation reduces local inflammatory mediator production and mast cell degranulation at the injury site, while central PPAR-alpha activation in spinal cord and supraspinal structures modulates descending pain facilitation and glial activation [34].

6.3 Neurodegenerative disease models

In transgenic mouse models of Alzheimer disease, chronic oral PEA administration reduces neuroinflammation, oxidative stress, and glutamate excitotoxicity, and preserves cognitive function. D'Agostino et al. (2012) demonstrated that PEA rescued cognitive deficits in the 3xTg-AD mouse model and reduced amyloid-beta deposition, astrogliosis, and microglial activation through a PPAR-alpha-dependent mechanism [16]. Subsequent studies by Scuderi et al. (2014, 2018) confirmed that ultramicrosized PEA counteracted reactive astrogliosis induced by beta-amyloid peptide and produced neuroprotective effects in multiple Alzheimer disease models [36, 37]. A 2025 study demonstrated that ultramicrosized PEA restores astrocyte-neuron metabolic coupling and Klotho/FGF21 signaling in a triple-transgenic mouse model [38].

In models of Parkinson disease, PEA reduces 6-hydroxydopamine-induced dopaminergic neuron loss and associated neuroinflammation. In experimental autoimmune encephalomyelitis, PEA reduces demyelination, immune cell infiltration, and clinical disease severity [15].

6.4 Other preclinical applications

PEA has demonstrated efficacy in preclinical models of ocular inflammation and glaucoma (reducing intraocular pressure and retinal ganglion cell loss), intestinal inflammation (reducing experimental colitis severity), pulmonary inflammation (reducing acute lung injury), and dermatological inflammation (reducing contact dermatitis and atopic dermatitis in murine models) [15, 22]. These applications reflect the broad distribution of the PPAR-alpha target and the mast cell modulatory mechanism across tissue compartments.

7. Clinical Evidence Base

7.1 Chronic and neuropathic pain

The most substantial clinical evidence for PEA is in chronic and neuropathic pain. Multiple randomized controlled trials have evaluated micronized and ultramicronized PEA as add-on therapy or monotherapy in various pain conditions.

A 2023 systematic review and meta-analysis by Scuteri et al. in *Nutrients*, encompassing 12 double-blind randomized controlled trials, reported that PEA supplementation produced statistically significant and clinically meaningful reduction in pain intensity compared to placebo or active control across multiple pain types (nociceptive, neuropathic, and mixed) [12]. Effect sizes were moderate, with pooled mean differences on visual analog scales ranging from 1.5 to 3.0 points on a 10-point scale. The effect was dose-dependent and time-dependent, with maximal benefit at 60 days of treatment at 1200 mg daily.

A 2024 meta-analysis by Artukoglu et al. in *Nutrition Reviews* confirmed these findings and reported that PEA significantly reduced pain intensity across 15 studies, with effects independent of patient age, sex, or pain type [13]. A further 2024 systematic review of micron-size PEA for extended treatment (60 days or more) encompassing 9 studies and 742 patients reported statistically and clinically significant pain reduction [14].

7.2 Sciatic pain and lumbar radiculopathy

Guida et al. (2010) conducted a randomized controlled trial of ultramicronized PEA 600 mg twice daily versus standard therapy alone in 636 patients with sciatic pain due to lumbar disc herniation. PEA-treated patients showed significantly greater pain reduction at 21 days and maintained benefit through day 60 [39]. This trial is the largest single randomized controlled trial of PEA for pain and provides the most robust evidence for the sciatic pain indication.

7.3 Diabetic peripheral neuropathy

Pickering et al. (2022) conducted a randomized double-blind placebo-controlled trial of ultramicronized PEA in 62 patients with painful diabetic peripheral neuropathy over 8 weeks. PEA treatment significantly reduced neuropathic pain scores, reduced inflammatory markers, improved sleep quality, and reduced depressive symptoms [40]. The compound was well tolerated with no treatment-related serious adverse events.

7.4 Carpal tunnel syndrome

Conigliaro et al. (2011) evaluated micronized PEA 600 mg twice daily as add-on therapy to standard conservative treatment in 26 patients with carpal tunnel syndrome with neuropathic pain. PEA treatment produced significant improvement in pain scores and nerve conduction parameters at 30 and 60 days compared to control [41].

7.5 Temporomandibular joint disorder

Marini et al. (2012) conducted a randomized double-blind controlled trial of PEA 300 mg twice daily versus ibuprofen 600 mg three times daily in 24 patients with temporomandibular joint inflammatory arthralgia. PEA produced comparable pain reduction to ibuprofen at 7 and 14 days, with superior improvement in maximum mouth opening [42].

7.6 Endometriosis-associated pelvic pain

Indraccolo and Barbieri (2010) evaluated micronized PEA 400 mg twice daily for 90 days in women with endometriosis-related chronic pelvic pain. PEA treatment produced significant reduction in pelvic pain and dyspareunia scores compared to baseline, with sustained benefit through the treatment period [43].

7.7 Neuroinflammatory and neurodegenerative indications

Clinical evidence in neuroinflammatory conditions is more limited than in pain. A 2018 open-label study evaluated ultramicronized PEA as adjunctive therapy in relapsing-remitting multiple sclerosis patients receiving interferon beta-1a, reporting reduced cutaneous adverse effects of interferon therapy and reduced circulating proinflammatory cytokines [44].

A 2024 study evaluated micronized/ultramicronized PEA 600 mg twice daily for 3 months in COVID-19 survivors with persistent fatigue and depressive symptoms. PEA-treated patients showed significantly greater improvement in depression scores and fatigue severity compared to untreated controls [45].

Clinical trials in Alzheimer disease, Parkinson disease, and stroke recovery are in early stages or are limited to case series and pilot studies. The preclinical evidence base is strong, but the clinical translation to neurodegenerative indications has not yet produced definitive randomized controlled trial results [15, 16].

7.8 Dermatological applications

Topical PEA has been evaluated in atopic dermatitis and eczema. A large multicenter observational study by Eberlein et al. (2007) in 2456 patients with atopic eczema demonstrated that a PEA-containing emollient cream reduced pruritus, erythema, excoriation, and lichenification over 4 to 6 weeks of application [32]. The study was open-label and observational; randomized controlled data for topical PEA in dermatological conditions are limited.

8. Sourcing and Quality Verification

PEA is available from multiple sources at varying quality grades. The principal categories are:

Pharmaceutical-quality formulated products: Normast (Epitech Group, Italy) is the original micronized/ultramicronized PEA product and is the preparation used in the majority of published clinical trials. Levagen (Gencor Pacific) is a patented cold-water-dispersible PEA formulation with enhanced bioavailability. PeaPure (JP Russell Science, Netherlands) is an ultramicronized preparation. These products are available in European and Australian markets as medical foods or foods for special medical purposes. Pricing is in the range of \$30 to \$80 per month at typical clinical doses (1200 mg daily).

Dietary supplement grade: Multiple supplement manufacturers produce PEA capsules and powders, typically at 300 to 600 mg per capsule. Formulation quality (particle size, excipient compatibility) varies substantially among supplement-grade products. Investigators should confirm that supplement-grade PEA is micronized and should not assume bioequivalence with the formulated pharmaceutical products used in clinical trials.

Research-grade chemical: PEA is available from Sigma-Aldrich, Cayman Chemical, Tocris, MedChemExpress, Santa Cruz Biotechnology, and other chemical suppliers at greater than 98 percent purity by HPLC. Research-grade material is supplied as the native crystalline powder (not micronized) in milligram to gram quantities. Pricing is moderate, typically \$30 to \$100 per gram.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography area-percent purity (target greater than 98 percent)
- Mass spectrometry confirmation of molecular weight (protonated molecular ion $[M+H]^+$ at m/z 300.29)
- Melting point determination (93 to 98 degrees Celsius for pure compound)
- Karl Fischer or loss-on-drying analysis for residual water content
- For micronized or ultramicronized preparations, particle size distribution analysis by laser diffraction

9. Reconstitution and Handling

PEA is a waxy solid at room temperature, freely soluble in dimethyl sulfoxide (DMSO), ethanol, chloroform, and methanol, and practically insoluble in water.

For in vitro research: Stock solutions are typically prepared at 10 to 100 mM in DMSO. Working concentrations for cell-based assays are typically 0.1 to 100 micromolar, requiring dilution of the DMSO stock into cell culture medium. Final DMSO concentration in the assay should not exceed 0.1 percent to avoid solvent cytotoxicity. Ethanol may be substituted for DMSO as a vehicle at comparable concentrations.

For in vivo research (rodent): PEA is typically administered as a suspension in vehicle containing carboxymethylcellulose (0.5 to 1 percent w/v), Tween 80 (0.1 percent v/v), and saline. For the micronized or ultramicrosized formulations, the reduced particle size permits more uniform suspension. Intraperitoneal doses of 1 to 30 mg/kg are standard in rodent anti-inflammatory and pain models. Oral (gavage) doses of 10 to 100 mg/kg are used for chronic administration studies.

Storage: Solid PEA should be stored at minus 20 degrees Celsius under desiccation for long-term stability. The compound is stable at room temperature for weeks to months if protected from moisture. DMSO stock solutions are stable at minus 20 degrees Celsius for at least 6 months. Aqueous suspensions should be prepared fresh before use.

Light sensitivity: PEA is not significantly photolabile. Light protection is not required but is reasonable practice for long-term storage of stock solutions.

Handling precautions: PEA is classified as a low-hazard research chemical. Standard laboratory personal protective equipment (gloves, safety glasses, laboratory coat) is appropriate. No special containment or ventilation requirements apply.

10. Stack Interactions and Combinations

PEA interacts with several drug classes and research compounds through its metabolic pathways and multi-target pharmacology. Investigators conducting research with PEA, especially in chronic dosing regimens or in combination with other compounds, should consider:

FAAH inhibitors: Compounds that inhibit FAAH (URB597, PF-04457845, and other experimental FAAH inhibitors) reduce PEA catabolism and elevate endogenous and exogenous PEA levels. The combination produces additive or synergistic anti-inflammatory and analgesic effects in preclinical models. The combination also elevates anandamide levels through the same enzymatic inhibition, producing a broader endocannabinoid-system potentiation [7, 29].

NAAA inhibitors: Inhibitors of NAAA (ARN077, ARN726) are the more selective strategy for elevating PEA levels, as NAAA is the principal PEA-degradative enzyme under physiological conditions. NAAA inhibitors produce anti-inflammatory effects that phenocopy exogenous PEA administration and are additive with exogenous PEA [8].

Cannabinoids and endocannabinoid system modulators: PEA and cannabidiol (CBD) have been reported to produce synergistic anti-nociceptive effects in mouse models of acute and chronic pain. The combination may exploit complementary mechanisms: PEA acting through PPAR-alpha and CBD acting through 5-HT1A, TRPV1, and other targets [46]. PEA and direct cannabinoid receptor agonists (THC, synthetic cannabinoids) have not been systematically characterized in combination but may produce additive analgesic and anti-inflammatory effects through convergent downstream pathways.

Nonsteroidal anti-inflammatory drugs (NSAIDs): PEA has been combined with ibuprofen, ketoprofen, and other NSAIDs in clinical studies without evidence of pharmacokinetic interaction or increased adverse events. The combination produces additive analgesia through complementary mechanisms (PPAR-alpha agonism plus cyclooxygenase inhibition) [42].

Opioid analgesics: PEA as add-on therapy to opioid regimens has been evaluated in some clinical pain studies. The combination does not produce characterized pharmacokinetic interactions. PEA may provide an opioid-sparing effect through additive analgesia, reducing the required opioid dose for equivalent pain control.

Luteolin and polyphenols: The combination of PEA with the flavonoid luteolin (available commercially as PEA-Lut or Glialia) has been evaluated in preclinical neurodegeneration models and in small clinical studies for neuroinflammation. Luteolin provides additional anti-inflammatory activity through mast cell stabilization and NF-kappaB inhibition, and the combination has produced additive neuroprotective effects in Alzheimer disease models [36, 47].

Acetylcholinesterase inhibitors: In neurodegenerative research, PEA has been administered concurrently with donepezil and other acetylcholinesterase inhibitors without evidence of interaction. The mechanisms are complementary (cholinergic potentiation plus anti-neuroinflammation).

CYP450 interactions: PEA is not metabolized by cytochrome P450 enzymes and does not inhibit or induce major CYP isoforms at pharmacologically relevant concentrations. Drug-drug interactions mediated through the CYP450 system are not expected.

11. Adverse Events and Safety

11.1 Safety profile overview

PEA exhibits a favorable safety profile consistent with its status as an endogenous lipid mediator and a natural dietary constituent. The compound has been evaluated in more than 40 clinical studies encompassing approximately 3000 patient-exposures at oral doses of 300 to 1200 mg daily for treatment durations of 7 to 120 days. No serious adverse drug reactions have been attributed to PEA supplementation in the published clinical literature [12, 13, 48].

11.2 Common adverse events

Adverse events reported in randomized controlled trials are rare and mild:

- Mild gastrointestinal discomfort (stomach upset, nausea): reported in fewer than 2 percent of treated patients across pooled trial data
- Brief palpitations: reported in isolated cases, self-limiting
- Mild headache: reported in fewer than 1 percent of treated patients

The incidence of adverse events in PEA-treated groups has been comparable to placebo in the majority of double-blind randomized controlled trials. No dose-response relationship for adverse events has been identified across the 300 to 1200 mg daily dose range [12, 48].

11.3 Toxicological assessment

A comprehensive preclinical toxicological assessment of micronized PEA (Della Valle et al., 2017) evaluated acute toxicity (2000 mg/kg single oral dose in rats), subchronic toxicity (1000 mg/kg/day oral for 90 days in rats), genotoxicity (Ames test, chromosomal aberration assay, in vivo micronucleus test), and reproductive toxicity. No evidence of toxicity, genotoxicity, or reproductive toxicity was observed at any tested dose [49]. The no-observed-adverse-effect level (NOAEL) in the 90-day subchronic study was 1000 mg/kg/day, the highest dose tested.

11.4 Long-term safety

For treatment durations beyond 60 days, the safety database is smaller. A 2016 systematic review by Paladini et al. noted that the total number of patients treated for more than 60 days was insufficient to rule out adverse drug reactions at an incidence of less than 1 in 100 [48]. Longer-term safety data from post-marketing surveillance and observational studies have not identified any signal of concern, but the formal statistical power for rare adverse event detection is limited.

11.5 Special populations

Pregnancy and lactation data are limited. PEA is an endogenous compound present in human tissues including placenta and breast milk, and no theoretical basis for teratogenicity exists. Animal reproductive toxicity studies have not demonstrated developmental toxicity. Clinical use in pregnancy and lactation has not been formally evaluated in controlled studies.

Pediatric use has been evaluated in limited studies for pain and neuroinflammatory conditions. No specific pediatric safety concerns have been identified.

No dose adjustment is required for renal or hepatic impairment on the basis of the metabolic pathway (amide hydrolysis to palmitic acid and ethanolamine, not CYP450-mediated hepatic biotransformation).

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five alternative anti-inflammatory lipid mediators or endocannabinoid-system-active compounds against palmitoylethanolamide, evaluated against five competency standards: novelty, effect size, promising potential (current clinical state and trajectory), side-effect profile, and overall validation. The five comparators were selected to represent the principal pharmacological alternatives within the N-acylethanolamide, phytocannabinoid, and specialized pro-resolving mediator classes.

12.1 Cannabidiol (CBD)

Mechanism: Cannabidiol is a phytocannabinoid from *Cannabis sativa* that acts through multiple targets including allosteric modulation of CB1, agonism at 5-HT1A receptors, agonism at TRPV1, antagonism at GPR55, and inhibition of adenosine reuptake. CBD does not produce the psychoactive effects of delta-9-tetrahydrocannabinol [50].

Novelty: Moderate. The multi-target mechanism is well characterized. CBD is the most extensively studied non-psychoactive cannabinoid and the subject of an approved pharmaceutical product (Epidiolex/Epidyolex for seizure disorders).

Effect size: In pain indications, clinical evidence for CBD is mixed. Randomized controlled trials in chronic pain have produced inconsistent results, with some studies showing modest benefit and others showing no difference from placebo. The effect size for analgesia is generally smaller and less consistent than that reported for PEA in comparable pain populations. In epilepsy, effect sizes are large and clinically significant at high doses (10 to 20 mg/kg/day).

Promising potential: High for seizure disorders (approved indication). Moderate for pain and inflammation, with substantial ongoing clinical trial activity.

Side-effect profile: CBD at pharmacological doses (greater than 300 mg daily) produces somnolence, diarrhea, decreased appetite, and hepatotoxicity (transaminase elevation) in a dose-dependent manner. Drug-drug interactions through CYP3A4 and CYP2C19 inhibition are clinically significant. The side-effect profile is more pronounced than that of PEA.

Overall validation: High for seizure disorders; moderate for pain and inflammation.

Comparison to PEA: CBD and PEA share some downstream anti-inflammatory and analgesic effects but operate through largely distinct receptor mechanisms. PEA has a superior safety profile (no hepatotoxicity, no CYP450 interactions, no somnolence) and more consistent analgesic efficacy in randomized controlled trials. CBD has the advantage of an approved drug indication (epilepsy) and broader public awareness. The two compounds may be synergistic when combined [46].

12.2 Oleoylethanolamide (OEA)

Mechanism: OEA is the unsaturated C18:1 N-acylethanolamide congener of PEA. Like PEA, OEA is an endogenous PPAR-alpha agonist, but with additional potent activity at GPR119 and a well-characterized anorexigenic effect mediated through vagal afferent signaling [51].

Novelty: Low. OEA and PEA share the PPAR-alpha mechanism and were characterized in the same research programs.

Effect size: For anti-inflammatory and analgesic effects, OEA and PEA produce comparable efficacy in preclinical models. OEA has more pronounced effects on appetite suppression and lipid metabolism. Clinical evidence for OEA in pain is limited compared to PEA; the majority of OEA clinical data pertain to metabolic and appetite endpoints.

Promising potential: Moderate for metabolic indications. Low for pain (insufficient clinical trial data).

Side-effect profile: Similar to PEA. No serious adverse events reported in the limited clinical studies.

Overall validation: Low to moderate. OEA is principally a research compound with limited clinical translation beyond metabolic applications.

Comparison to PEA: OEA and PEA are structurally related endogenous PPAR-alpha agonists with overlapping but not identical pharmacology. PEA has substantially more clinical evidence for pain and neuroinflammation. OEA has more evidence for appetite and metabolic regulation. The two may be complementary for combined anti-inflammatory and metabolic applications.

12.3 Stearoylethanolamide (SEA)

Mechanism: SEA is the saturated C18:0 N-acylethanolamide. It is an endogenous compound with reported anti-inflammatory activity, though the receptor pharmacology is less well characterized than that of PEA. Some evidence supports PPAR-alpha and PPAR-gamma activation, and SEA has been reported to induce apoptosis in certain cancer cell lines [52].

Novelty: Low. SEA is the least studied of the major endogenous N-acylethanolamides.

Effect size: Preclinical anti-inflammatory effects are modest and less consistent than PEA. No clinical efficacy data exist for any indication.

Promising potential: Low. SEA is principally a research tool compound.

Side-effect profile: Not characterized in clinical studies. Preclinical toxicology data are limited.

Overall validation: Low. The compound lacks clinical development and has a limited preclinical evidence base compared to PEA.

Comparison to PEA: PEA is superior to SEA on all comparator standards. SEA serves as a structural and pharmacological reference compound within the N-acylethanolamide family but does not represent a clinical alternative.

12.4 Anandamide (N-arachidonylethanolamide, AEA)

Mechanism: Anandamide is the prototypical endocannabinoid, acting as a partial agonist at CB1 and CB2 receptors and as a full agonist at TRPV1. It is biosynthesized and degraded by the same enzymatic pathways as PEA (NAPE-PLD biosynthesis, FAAH degradation) and is the endocannabinoid whose signaling is potentiated by PEA through the entourage mechanism [11, 29].

Novelty: Low. Anandamide was the first endocannabinoid identified (Devane et al., 1992) and is the most extensively characterized compound in the endocannabinoid system.

Effect size: Anandamide produces potent analgesic and anti-inflammatory effects in preclinical models but has extremely limited clinical utility owing to rapid enzymatic degradation (plasma half-life less than 5 minutes) and psychoactive effects at CB1-activating concentrations.

Promising potential: Low as an exogenous therapeutic agent. High as a target for indirect modulation (FAAH inhibitors, PEA entourage).

Side-effect profile: Direct administration produces CB1-mediated psychoactive effects (sedation, impaired cognition, potential for abuse) that fundamentally limit clinical utility. PEA avoids these effects by modulating anandamide levels locally rather than activating CB1 directly.

Overall validation: High as an endogenous signaling molecule; low as an exogenous therapeutic.

Comparison to PEA: PEA and anandamide are metabolically linked through the entourage mechanism but have fundamentally different therapeutic profiles. PEA is orally bioavailable, non-psychoactive, and clinically applicable; anandamide is not. The comparison illustrates the advantage of the PEA approach: modulating the endocannabinoid system indirectly through PPAR-alpha agonism and FAAH competition rather than directly through cannabinoid receptor activation.

12.5 Resolvin E1 (RvE1)

Mechanism: Resolvin E1 is a specialized pro-resolving lipid mediator derived from eicosapentaenoic acid (EPA, an omega-3 fatty acid). RvE1 acts through the receptors ChemR23 (CMKLR1) and BLT1 to promote resolution of inflammation, enhance macrophage phagocytosis of apoptotic cells, and reduce neutrophil infiltration. RvE1 represents a mechanistically distinct class of endogenous anti-inflammatory lipid from the N-acylethanolamides [53].

Novelty: High. The specialized pro-resolving mediator class (resolvins, protectins, maresins) was characterized principally by the Serhan laboratory beginning in 2002 and represents a paradigm shift in inflammation biology from inhibition of pro-inflammatory mediators to active promotion of resolution.

Effect size: Potent anti-inflammatory and pro-resolving effects in preclinical models at nanomolar to low-microgram doses. RvE1 is approximately 100 to 1000-fold more potent than PEA on a molar basis in certain inflammatory models.

Promising potential: Moderate. RvE1 and related resolvins are in early clinical development. Pharmaceutical formulation challenges (lipid instability, rapid metabolism, nanomolar dosing requirements) have limited clinical translation.

Side-effect profile: No adverse effects reported in preclinical studies. Clinical safety data are extremely limited.

Overall validation: Moderate. Strong preclinical evidence base; limited clinical translation.

Comparison to PEA: RvE1 and PEA represent complementary endogenous anti-inflammatory mechanisms: PEA operates through PPAR-alpha nuclear transcription and mast cell modulation, while RvE1 operates through specialized pro-resolving receptor signaling. PEA has the substantial advantage of oral bioavailability, clinical trial validation, and commercial availability. RvE1 has the advantage of higher preclinical potency and a mechanistically novel pro-resolution mechanism that may complement PEA anti-inflammatory activity.

12.6 Comparator summary

PEA occupies a distinctive position among endogenous anti-inflammatory lipid mediators. It is the only compound in this comparator panel with a substantial body of positive randomized controlled trial evidence in chronic and neuropathic pain, a favorable safety profile demonstrated across more than 3000 patient-exposures, oral bioavailability in micronized formulations, absence of psychoactive or sedative effects, absence of CYP450-mediated drug-drug interactions, and broad commercial availability. **Cannabidiol** has broader public awareness and an approved seizure indication but a more pronounced side-effect profile and less consistent analgesic efficacy. **Oleoylethanolamide** is a close structural congener with overlapping pharmacology but limited clinical pain data. **Stearoylethanolamide** lacks clinical development. **Anandamide** is the endocannabinoid whose signaling PEA potentiates but is not a viable exogenous therapeutic. **Resolvin E1** represents a mechanistically novel pro-resolution approach with high preclinical potency but limited clinical translation.

The principal practical advantage of PEA for research and clinical applications is the combination of multi-target endogenous pharmacology, demonstrated clinical analgesic efficacy, favorable safety, and oral bioavailability in commercially available formulations. Investigators considering PEA for anti-inflammatory or analgesic research should use micronized or ultramicronized formulations, should expect moderate effect sizes consistent with the clinical trial literature, and should consider the comparator landscape as context for positioning PEA within multi-target anti-inflammatory and neuroprotective research programs.

13. References

1. Kuehl FA Jr, Jacob TA, Ganley OH, Ormond RE, Meisinger MAP. The identification of N-(2-hydroxyethyl)-palmitamide as a naturally occurring anti-inflammatory agent. *J Am Chem Soc.* 1957;79(20):5577-5578.
2. Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. *Br J Pharmacol.* 2017;174(11):1349-1365.
3. Impellizzeri D, Bruschetta G, Cordaro M, et al. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. *J Neuroinflammation.* 2014;11:136.
4. Iannotti FA, Di Marzo V, Petrosino S. Endocannabinoids and endocannabinoid-related mediators: targets, metabolism and role in neurological disorders. *Prog Lipid Res.* 2016;62:107-128.
5. Esposito E, Cuzzocrea S. Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries. *CNS Neurol Disord Drug Targets.* 2013;12(1):55-61.
6. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. *J Biol Chem.* 2004;279(7):5298-5305.
7. Ueda N, Yamanaka K, Yamamoto S. Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. *J Biol Chem.* 2001;276(38):35552-35557.
8. Tsuboi K, Sun YX, Okamoto Y, Araki N, Tonai T, Ueda N. Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the cholesteryl glycerophospholipase family with structural and functional similarity to acid ceramidase. *J Biol Chem.* 2005;280(12):11082-11092.
9. Aloe L, Leon A, Levi-Montalcini R. A proposed autacoid mechanism controlling mastocyte behaviour. *Agents Actions.* 1993;39(Spec No):C145-C147.
10. Lo Verme J, Fu J, Astarita G, et al. The nuclear receptor peroxisome proliferator-activated receptor- α mediates the anti-inflammatory actions of palmitoylethanolamide. *Mol Pharmacol.* 2005;67(1):15-19.
11. Ben-Shabat S, Fride E, Sheskin T, et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. *Eur J Pharmacol.* 1998;353(1):23-31.
12. Scuteri D, Guilianno C, Rombolà L, et al. Palmitoylethanolamide in the treatment of chronic pain: a systematic review and meta-analysis of double-blind randomized controlled trials. *Nutrients.* 2023;15(6):1350.
13. Artukoglu BB, Beyer C, Gialluisi A, et al. Meta-analysis of palmitoylethanolamide in pain management: addressing literature gaps and enhancing understanding. *Nutr Rev.* 2024;83(7):e1604.

14. Lang-Illievich K, Bornemann-Cimenti H, Gajic V, et al. Extended treatment with micron-size oral palmitoylethanolamide (PEA) in chronic pain: a systematic review and meta-analysis. *Nutrients*. 2024;16(11):1653.
15. Petrosino S, Moriello AS. Palmitoylethanolamide: a nutritional approach to keep neuroinflammation within physiological boundaries. A systematic review. *Int J Mol Sci*. 2020;21(24):9526.
16. D'Agostino G, Russo R, Cennamo V, et al. Palmitoylethanolamide protects against the amyloid-beta25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease. *Neuropsychopharmacology*. 2012;37(7):1784-1792.
17. Petrosino S, Cordaro M, Verde R, et al. Oral ultramicronized palmitoylethanolamide: plasma and tissue levels and spinal anti-hyperalgesic effect. *Front Pharmacol*. 2018;9:249.
18. Coburn AF, Graham CE, Haninger J. The effect of egg yolk in diets on anaphylactic arthritis (passive Arthus phenomenon) in the guinea pig. *J Exp Med*. 1954;100(5):425-435.
19. Long DA, Martin AJ. Factor in arachis oil depressing sensitivity to tuberculin in B.C.G.-infected guineapigs. *Lancet*. 1956;270(6921):464-468.
20. Masek K, Perlík F, Klima J, Kahlich R. Prophylactic efficacy of N-2-hydroxyethyl palmitamide (Impulsin) in acute respiratory tract infections. *Eur J Clin Pharmacol*. 1974;7(6):415-419.
21. Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A. Nerve growth factor: from neurotrophin to neurokin. *Trends Neurosci*. 1996;19(11):514-520.
22. Mattace Raso G, Russo R, Calignano A, Meli R. Palmitoylethanolamide in CNS health and disease. *Pharmacol Res*. 2014;86:32-41.
23. Cerrato S, Brazis P, della Valle MF, Miolo A, Puigdemont A. Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNF α release from canine skin mast cells. *Vet Immunol Immunopathol*. 2010;133(1):9-15.
24. Facci L, Dal Toso R, Bhatt DK, Leon A, Bhatt DK, Bhatt DK. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. *Proc Natl Acad Sci U S A*. 1995;92(8):3376-3380.
25. De Filippis D, D'Amico A, Blasi MO, et al. Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell mediator release and group II metabotropic glutamate receptor signalling. *Eur J Pharmacol*. 2010;636(1-3):64-71.
26. Ryberg E, Larsson N, Sjögren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. *Br J Pharmacol*. 2007;152(7):1092-1101.
27. Godlewski G, Offertaler L, Wagner JA, Kunos G. Receptors for acylethanolamides: GPR55 and GPR119. *Prostaglandins Other Lipid Mediat*. 2009;89(3-4):105-111.
28. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Bhatt DK. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. *Proc Natl Acad Sci U S A*. 2008;105(7):2699-2704.

29. Ho WS, Barrett DA, Randall MD. "Entourage" effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. *Br J Pharmacol.* 2008;155(6):837-846.
30. Lo Verme J, Gaetani S, Fu J, Oveisi F, Burton K, Piomelli D. Regulation of food intake by oleoylethanolamide. *Cell Mol Life Sci.* 2005;62(6):708-716.
31. Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. *Br J Clin Pharmacol.* 2016;82(4):932-942.
32. Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). *J Eur Acad Dermatol Venereol.* 2007;21(8):1128-1135.
33. Esposito E, Paterniti I, Mazzon E, et al. Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. *Brain Behav Immun.* 2011;25(6):1099-1112.
34. Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. *Pain.* 2008;139(3):541-550.
35. Bettoni I, Comelli F, Colombo A, Bonfanti P, Costa B. Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide. *CNS Neurol Disord Drug Targets.* 2013;12(1):34-44.
36. Scuderi C, Stecca C, Valenza M, et al. Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease. *Cell Death Dis.* 2014;5(9):e1419.
37. Scuderi C, Bronzuoli MR, Fez R, et al. Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer's disease by exerting anti-inflammatory and neuroprotective effects. *Transl Psychiatry.* 2018;8(1):32.
38. Ferrara L, et al. Ultramicronized palmitoylethanolamide restores astrocyte-neuron metabolic coupling and Klotho/FGF21 signaling in a triple-transgenic mouse model of Alzheimer's disease. *CNS Neurosci Ther.* 2025;31(6):e70474.
39. Guida G, De Martino M, De Fabiani A, et al. La palmitoiletanolamide (Normast) en el dolor neuropatico cronico por lumbociatalgia de tipo compresivo: estudio clinico multicentrico. *Dolor.* 2010;25:35-42.
40. Pickering E, Steels EL, Steadman KJ, et al. A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain. *Inflammopharmacology.* 2022;30(6):2063-2077.
41. Conigliaro R, Drago V, Foster PS, Schiber C, Schiber D, Novo SF. Use of palmitoylethanolamide in the entrapment neuropathy of the median in the wrist. *Minerva Med.* 2011;102(2):141-147.
42. Marini I, Bartolucci ML, Bortolotti F, Gatto MR, Bonetti GA. Palmitoylethanolamide versus a non-steroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. *J Orofac Pain.* 2012;26(2):99-104.

43. Indraccolo U, Barbieri F. Effect of palmitoylethanolamide-polydatin combination on chronic pelvic pain associated with endometriosis: preliminary observations. *Eur J Obstet Gynecol Reprod Biol.* 2010;150(1):76-79.
44. Orefice NS, Alhouayek M, Caber A, et al. Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-beta1a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis. *Neurotherapeutics.* 2016;13(4):897-912.
45. Versace V, Ortelli P, Dezi S, et al. Micronized/ultramicronized palmitoylethanolamide improves depression and fatigue in coronavirus disease 2019 (COVID-19) survivors. *Int Clin Psychopharmacol.* 2024;39(6):364-370.
46. Guilherme-Fernandes J, Costa J, Rodrigues L, et al. Palmitoylethanolamide and hemp oil extract exert synergistic anti-nociceptive effects in mouse models of acute and chronic pain. *Pharmacol Res.* 2021;167:105545.
47. Caltagirone C, Cisari C, Schiber C, et al. Co-ultramicronized palmitoylethanolamide/luteolin in the treatment of cerebral ischemia: from rodent to man. *Transl Stroke Res.* 2016;7(1):54-69.
48. Paladini A, Fusco M, Cenacchi T, Schievano C, Piroli A, Varrassi G. Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis. *Pain Physician.* 2016;19(2):11-24.
49. Della Valle MF, Colloca L, Bhatt R, et al. Safety of micronized palmitoylethanolamide (microPEA): lack of toxicity and genotoxic potential. *Food Nutr Sci.* 2017;8:746-766.
50. Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. *J Clin Pharmacol.* 2002;42(S1):11S-19S.
51. Fu J, Gaetani S, Oveisi F, et al. Oleyethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. *Nature.* 2003;425(6953):90-93.
52. Maccarrone M, Pauselli R, Di Rienzo M, Finazzi-Agrò A. Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. *Biochem J.* 2002;366(Pt 1):137-144.
53. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. *J Exp Med.* 2000;192(8):1197-1204.

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly. Palmitoylethanolamide is not approved as a drug by the United States Food and Drug Administration or by the European Medicines Agency. It is marketed as a dietary supplement, medical food, or food for special medical purposes in various jurisdictions; investigators should consult their local regulatory authority before any human research application. Micronized and ultramicronized formulations are the preparations used in the majority of published clinical trials and should not be assumed to be bioequivalent to native crystalline PEA.